Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v3.20.4
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Treasury Stock
Common stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance, beginning at Sep. 30, 2018   $ 573 $ (517) $ (41,952) $ (41,896)
Balance, beginning, shares at Sep. 30, 2018   5,727,090      
Stock-based compensation expense     8,958,966   8,958,966
Repurchase of common stock $ (140)   126   $ (14)
Repurchase of common stock (in shares) (1,401,202)       (1,375,000)
Retirement of common stock $ 140 $ (140)      
Retirement of common stock (in shares) 1,401,202 (1,401,202)      
Common stock for research and development expense- license acquired - CMU   $ 84 844,516   $ 844,600
Common stock for research and development expense- license acquired - CMU (in shares)   835,625      
Issuance of restricted stock for services   $ 153 1,321   1,474
Issuance of restricted stock for services (in shares)   1,532,984      
Cash received for prefunded warrants     10   10
Issuance of common stock for conversion of notes payable and accrued interest   $ 61 966,155   966,216
Issuance of common stock for conversion of notes payable and accrued interest (in shares)   609,874      
Issuance of common stock for the cashless exercise of warrants   $ 10 429,667   429,677
Issuance of common stock for the cashless exercise of warrants (in shares)   103,787      
Issuance of common stock in pre-acquisition private placement, net of issuance costs   $ 530 8,267,627   8,268,157
Issuance of common stock in pre-acquisition private placement, net of issuance costs (in shares)   5,302,005      
Issuance of common stock and options for acquisition of Ohr   $ 283 11,776,644   11,776,927
Issuance of common stock and options for acquisition of Ohr (in shares)   2,829,248      
Issuance of common stock in a private placement financing, net of issuance costs   $ 154 4,957,243   $ 4,957,397
Issuance of common stock in a private placement financing, net of issuance costs (in shares)   1,538,462      
Exercise of stock options (in shares)         0
Net loss       (26,132,130) $ (26,132,130)
Balance, ending at Sep. 30, 2019   $ 1,708 36,201,758 (26,174,082) $ 10,029,384
Balance, ending, shares at Sep. 30, 2019   17,077,873     17,077,873
Stock-based compensation expense     5,194,784   $ 5,194,784
Issuance of common stock, net of issuance costs   $ 604 33,283,366   33,283,970
Issuance of common stock, net of issuance costs (in shares)   6,037,500      
Issuance of restricted stock for services (in shares)   6,980      
Exercise of stock options   $ 3 171,027   $ 171,030
Exercise of stock options (in shares)   31,731     31,731
Net loss       (17,384,520) $ (17,384,520)
Balance, ending at Sep. 30, 2020   $ 2,315 $ 74,850,935 $ (43,558,602) $ 31,294,648
Balance, ending, shares at Sep. 30, 2020   23,154,084     23,154,084